On January 8, 2025, PolyPeptide Group announced a roughly €100 million investment to double solid-phase peptide synthesis (SPPS) capacity at its Malmö, Sweden plant, adding around 100 permanent jobs. The expansion is mainly tied to a long-standing GLP-1 customer agreement under one of the company's large commercial deals, with revenue contribution expected to begin in 2028. It reflects the global manufacturing crunch driven by GLP-1 agonist demand, which has outstripped existing peptide-API capacity and triggered comparable multi-hundred-million-euro build-outs at rivals such as Bachem and Lonza. Modular pre-built units were installed on-site during 2025 so existing production could keep running through the build-out.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.